First Manhattan Co. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 529,696 shares of the medical research company’s stock after selling 2,419 shares during the period. Thermo Fisher Scientific makes up about 0.6% of First Manhattan Co.’s investment portfolio, making the stock its 28th biggest position. First Manhattan Co.’s holdings in Thermo Fisher Scientific were worth $100,578,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock worth $4,640,970,000 after buying an additional 629,093 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock worth $4,074,828,000 after buying an additional 366,584 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after buying an additional 3,973,136 shares during the last quarter. Capital World Investors boosted its stake in shares of Thermo Fisher Scientific by 6.1% in the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after buying an additional 671,637 shares during the last quarter. Finally, Longview Partners Guernsey LTD boosted its stake in shares of Thermo Fisher Scientific by 7.4% in the 3rd quarter. Longview Partners Guernsey LTD now owns 4,564,913 shares of the medical research company’s stock worth $863,682,000 after buying an additional 313,782 shares during the last quarter. Hedge funds and other institutional investors own 86.22% of the company’s stock.

Thermo Fisher Scientific Inc. (NYSE:TMO) traded up $1.10 during midday trading on Monday, reaching $213.51. The company had a trading volume of 1,439,800 shares, compared to its average volume of 1,577,492. The stock has a market capitalization of $85,730.00, a P/E ratio of 36.25, a PEG ratio of 1.74 and a beta of 1.06. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc. has a 12 month low of $140.00 and a 12 month high of $214.57.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.03 earnings per share. sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, January 15th. Shareholders of record on Friday, December 15th were issued a dividend of $0.15 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday. Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. BTIG Research started coverage on Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 target price on the stock. Leerink Swann lifted their target price on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research report on Monday, October 9th. Finally, Evercore ISI started coverage on Thermo Fisher Scientific in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $212.21.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.49% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “First Manhattan Co. Reduces Stake in Thermo Fisher Scientific Inc. (TMO)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2018/01/22/first-manhattan-co-reduces-stake-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.